Thymoquinone prevents RANKL-induced osteoclastogenesis activation and osteolysis in an in vivo model of inflammation by suppressing NF-KB and MAPK Signalling

Pharmacological Research

Volumn 99, Issue , 2015, Pages 63-73

  Thummuri, Dinesh ^a   Jeengar, Manish Kumar ^a   Shrivastava, Shweta ^a   Nemani, Harishankar ^b   Ramavat, Ravindar Naik ^b   Chaudhari, Pradip ^c   Naidu, V G M ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b NATIONAL INSTITUTE OF NUTRITION   (India)

^c TATA MEMORIAL HOSPITAL   (India)

Author keywords

NF KB; Osteoclastogenesis; Osteolysis; RANKL; Thymoquinone

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; DENDRITIC CELL SPECIFIC TRANSMEMBRANE PROTEIN; HYDROGEN PEROXIDE; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MEMBRANE PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN C FOS; REACTIVE OXYGEN METABOLITE; THYMOQUINONE; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; UNCLASSIFIED DRUG; BENZOQUINONE DERIVATIVE; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; CONTROLLED STUDY; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; 3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CYTOLOGY; DRUG EFFECTS; ETIOLOGY; METABOLISM; OSTEOCLAST; PATHOLOGY; PHOSPHORYLATION; PREVENTION AND CONTROL; RAW 264.7 CELL LINE;

3T3 CELLS; ANIMALS; BENZOQUINONES; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; NF-KAPPA B; OSTEOCLASTS; OSTEOLYSIS; OXIDATIVE STRESS; PHOSPHORYLATION; RANK LIGAND; RAW 264.7 CELLS;

EID: 84930960083     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.05.006     Document Type: Article

References (46)

1. T.C.A. Phan, J. Xu, and M.H. Zheng Interaction between osteoblast and osteoclast: impact in bone disease Histol. Histopathol. 19 2004 1325 1344
2. Z.H. Lee, and H.-H. Kim Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts Biochem. Biophys. Res. Commun. 305 2003 211 214
3. W.J. Boyle, W.S. Simonet, and D.L. Lacey Osteoclast differentiation and activation Nature 423 2003 337 342
4. H. Takayanagi The role of NFAT in osteoclast formation Ann. N. Y. Acad. Sci. 1116 2007 227 237
5. F. Ikeda, R. Nishimura, T. Matsubara, S. Tanaka, J.-I. Inoue, and S.V. Reddy Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation J. Clin. Investig. 114 2004 475 484
6. J. Jeon, and D. Puleo Formulations for intermittent release of parathyroid hormone (1-34) and local enhancement of osteoblast activities Pharm. Dev. Technol. 13 2008 505 512
7. P. Morley, J.F. Whitfield, and G.E. Willick Parathyroid hormone an anabolic treatment for osteoporosis Curr. Pharm. Des. 7 2001 671 687
8. M.A. Perazella, and G.S. Markowitz Bisphosphonate nephrotoxicity Kidney Int. 74 2008 1385 1393
9. C. Dannemann, K.W. Graitz, M.O. Riener, and R.A. Zwahlen Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder Bone 40 2007 828 834
10. F. Vaillancourt, P. Silva, Q. Shi, H. Fahmi, J.C. Fernandes, and M. Benderdour Elucidation of molecular mechanisms underlying the protective effects of thymoquinone against rheumatoid arthritis J. Cell. Biochem. 112 2011 107 117
11. H. Ozdemir, M.I. Kara, K. Erciyas, H. Ozer, and S. Ay Preventive effects of thymoquinone in a rat periodontitis model: a morphometric and histopathological study J. Periodontal Res. 47 2012 74 80
12. A. Wirries, A.-K. Schubert, R. Zimmermann, S. Jabari, S. Ruchholtz, and N. El-Najjar Thymoquinone accelerates osteoblast differentiation and activates bone morphogenetic protein-2 and ERK pathway Int. Immunopharm. 15 2013 381 386
13. V. Naidu, U.M. Bandari, A.K. Giddam, K.R.D. Babu, J. Ding, and K.S. Babu Apoptogenic activity of ethyl acetate extract of leaves of Memecylon edule on human gastric carcinoma cells via mitochondrial dependent pathway Asian Pac. J. Trop. Med. 6 2013 337 345
14. Z. Zhai, H. Li, G. Liu, X. Qu, B. Tian, and W. Yan Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo Br. J. Pharmacol. 171 2014 663 675
15. S. Shrivastava, P. Kulkarni, D. Thummuri, M.K. Jeengar, V.G.M. Naidu, and M. Alvala Piperlongumine, an alkaloid causes inhibition of PI3K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells Apoptosis 19 2014 1148 1164
16. D. Thummuri, M.K. Jeengar, S. Shrivastava, A. Areti, V.G. Yerra, and S. Yamjala Boswellia ovalifoliolata abrogates ROS mediated NF-κB activation, causes apoptosis and chemosensitization in Triple Negative Breast Cancer cells Environ. Toxicol. Pharmacol. 38 2014 58 70
17. A. Oeckinghaus, and S. Ghosh The NF-κB family of transcription factors and its regulation Cold Spring Harbor Perspect. Biol. 1 2009 a000034
18. K. Brown Is tamoxifen a genotoxic carcinogen in women? Mutagenesis 24 2009 391 404
19. F. Rossi, G. Bellini, L. Luongo, S. Mancusi, M. Torella, and C. Tortora The 17-β-oestraadiol inhibits osteoclast activity by increasing the cannabinoid CB2 receptor expression Pharmacol. Res. 68 2013 7 15
20. Retrieved May 15 2015 from http://www.medscape.com/viewarticle/832009.
21. M. Karin Inflammation-activated protein kinases as targets for drug development Proc. Am. Thorac. Soc. 2 2005 386 390
22. M. Matsumoto, T. Sudo, T. Saito, H. Osada, and M. Tsujimoto Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-κB ligand (RANKL) J. Biol. Chem. 275 2000 31155 31161
23. S. Abbas, J. Clohisy, and Y. Abu-Amer Mitogen-activated protein (MAP) kinases mediate PMMA-induction of osteoclasts J. Orthop. Res. 21 2003 1041 1048
24. K.-Y. Han, D. Yang, E.-J. Chang, Y. Lee, H. Huang, and S.H. Sung Inhibition of osteoclast differentiation and bone resorption by sauchinone Biochem. Pharmacol. 74 2007 911 923
25. S. Bandyopadhyay, J.-M. Lion, R. Mentaverri, D.A. Ricupero, S. Kamel, and J.R. Romero Attenuation of osteoclastogenesis and osteoclast function by apigenin Biochem. Pharmacol. 72 2006 184 197
26. A.M. Al-Amri, and A.O. Bamosa Phase I safety and clinical activity study of thymoquinone in patients with advanced refractory malignant disease Shiraz E Med. J. 10 2009 107 111
27. F.R. Dehkordi, and A.F. Kamkhah Antihypertensive effect of Nigella sativa seed extract in patients with mild hypertension Fundam. Clin. Pharmacol. 22 2008 447 452
28. I.U. Bhatti, F.U. Rehman, M. Khan, and S. Marwat Effect of prophetic medicine kalonji (Nigella sativa L.) on lipid profile of human beings. An in vivo approach World Appl. Sci. J. 6 2009 1053 1057
29. S. Darakhshan, A.B. Pour, A.H. Colagar, and S. Sisakhtnezhad Thymoquinone and its therapeutic potentials Pharmacol. Res. 95 2015 138 158
30. T. Yi, S.-G. Cho, Z. Yi, X. Pang, M. Rodriguez, and Y. Wang Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways Mol. Cancer Therap. 7 2008 1789 1796
31. G. Sethi, K.S. Ahn, and B.B. Aggarwal Targeting nuclear factor-κB activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis Mol. Cancer Res. 6 2008 1059 1070
32. S. Rajput, B.N.P. Kumar, S. Sarkar, S. Das, B. Azab, and P.K. Santhekadur Targeted apoptotic effects of thymoquinone and tamoxifen on XIAP mediated Akt regulation in breast cancer PLOS ONE 8 2013 e61342
33. L. Galibert, M.E. Tometsko, D.M. Anderson, D. Cosman, and W.C. Dougall The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-κB, a member of the TNFR superfamily J. Biol. Chem. 273 1998 34120 34127
34. G. Franzoso, L. Carlson, L. Xing, L. Poljak, E.W. Shores, and K.D. Brown Requirement for NF-KB in osteoclast and B-cell development Genes Dev. 11 1997 3482 3496
35. S. Vaira, M. Alhawagri, I. Anwisye, H. Kitaura, R. Faccio, and D.V. Novack RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice J. Clin. Investig. 118 2008 2088 2097
36. X-c Bai, D. Lu, A-l Liu, Z-m Zhang, X-m Li, and Z-p Zou Reactive oxygen species stimulates receptor activator of NF-κB ligand expression in osteoblast J. Biol. Chem. 280 2005 17497 17506
37. N.K. Lee, Y.G. Choi, J.Y. Baik, S.Y. Han, D.-W. Jeong, and Y.S. Bae A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation Blood 106 2005 852 859
38. L. Gambari, G. Lisignoli, L. Cattini, C. Manferdini, A. Facchini, and F. Grassi Sodium hydrosulfide inhibits the differentiation of osteoclast progenitor cells via NRF2-dependent mechanism Pharmacol. Res. 87 2014 99 112
39. J. Kundu, D.-H. Kim, J.K. Kundu, and K.-S. Chun Thymoquinone induces heme oxygenase-1 expression in HaCaT cells via Nrf2/ARE activation: Akt and AMPK as upstream targets Food Chem. Toxicol. 65 2014 18 26
40. S.L. Teitelbaum RANKing c-Jun in osteoclast development J. Clin. Investig. 114 2004 463 465
41. Z.-Q. Wang, C. Ovitt, A.E. Grigoriadis, U. Mohle-Steinlein, U. Ruther, and E.F. Wagner Bone and haematopoietic defects in mice lacking c-fos Nature 360 1992 741 745
42. H. Takayanagi, S. Kim, T. Koga, H. Nishina, M. Isshiki, and H. Yoshida Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts Dev. Cell 3 2002 889 901
43. S.C. Manolagas, T. Bellido, and R.L. Jilka New insights into the cellular, biochemical, and molecular basis of postmenopausal and senile osteoporosis: roles of IL-6 and gp130 Int. J. Immunopharmacol. 17 1995 109 116
44. J. Lam, S. Takeshita, J.E. Barker, O. Kanagawa, F.P. Ross, and S.L. Teitelbaum TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand J. Clin. Investig. 106 2000 1481 1488
45. Q.-Q. Huang, and R.M. Pope The role of toll-like receptors in rheumatoid arthritis Curr. Rheumatol. Rep. 11 2009 357 364
46. K. Fuller, C. Murphy, B. Kirstein, S.W. Fox, and T.J. Chambers TNFα potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL Endocrinology 143 2002 1108 1118